Core Viewpoint - The company Meihao Medical (301363) has shown mixed financial performance, with revenue growth but a decline in net profit, indicating potential challenges in profitability despite stable revenue growth [2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, an increase of 3.28% year-on-year [2]. - The net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% year-on-year [2]. - The net profit excluding non-recurring items was 203 million yuan, down 17.85% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year [2]. - The single-quarter net profit attributable to shareholders was 93.90 million yuan, an increase of 5.89% year-on-year [2]. - The single-quarter net profit excluding non-recurring items was 92.70 million yuan, up 9.56% year-on-year [2]. - The company's debt ratio stands at 11.43%, with investment income of 4.90 million yuan and financial expenses of -27.39 million yuan [2]. - The gross profit margin is reported at 39.34% [2]. Market Activity - As of February 4, 2026, Meihao Medical's stock closed at 32.02 yuan, with a slight increase of 0.25% [1]. - The trading volume was 91,300 hands, with a total transaction value of 289 million yuan [1]. - The net inflow of main funds was 1.9749 million yuan, accounting for 0.68% of the total transaction value [1]. - Retail investors showed a net inflow of 9.0572 million yuan, representing 3.14% of the total transaction value [1]. - Over the past 90 days, seven institutions have rated the stock as a buy, with an average target price of 24.57 yuan [3].
股票行情快报：美好医疗（301363）2月4日主力资金净买入197.49万元